Krishna Naik
1. Sri Krishnadevaraya Univerisity, Anantapur, Andhra Pradesh, India. 2. ICFAI Foundation for Higher Education, Hyderabad, Andhra Pradesh, India.
Keywords: Phenyl hydrdrazones, Synthesis, Structural elucidation, Antibacterial activity, Antifungal activity.

Purpose: To synthesise, charecterise phenyl hydrazones namely, {4-[3-methyl-5-oxo-4-(phenyl hydrazono)-4,5-dihydro-pyrazol-1-yl]-phenoxy}-acetic acid N|-(4-substituted-thiazole-2-yl)-hydrazide VII and to evaluate the antibacrial activity. Methods: The synthesis of title compounds has been schemed elaborately and the structures of the compounds were established by elemental analysis, IR, 1H NMR and mass spectra. The antibacterial activity of the title compounds were evaluated against Staphylococcus aureus NCCS 2079 and Bacillus cereus NCCS 2106, Escherichia coli NCCS 265 and Pseudomonas aeruginosa NCCS 2200 and antifungal activity evaluated against Aspergillus niger NCCS 1196, Candida albicans NCCS 2106 by disk diffusion method. Results: The screened data reveal that the studied phenyl hydrazones under study exhibited promising antimicrobial activity against all the tested microbes. The antimicrobial activity of title compounds were compared with that of standadards. The title compounds with p-nitrophenyl, p-chlorophenyl, p-bromophenyl were more active agaist bacteria, where as the compounds with substituents namely phenyl, p-tolyl, p-anisyl, p-hydroxyphenyl, p-nitrophenyl were more active against fungi than the other compounds under investigation. Conclusion: Among the ten novel phenyl hydrazones synthesised {4-[3-methyl-5-oxo-4-(phenyl hydrazono)-4,5-dihydro-pyrazol-1-yl]-phenoxy}-acetic acid N|-(4-(4-nitro-phenyl)-thiazole-2-yl)-hydrazide was found the most active than the others. The other compounds demonstrated moderate activity against the tested microorganisms.

Article Information

Identifiers and Pagination:
First Page:16
Last Page:26
Publisher Id:JAppPharm (2013 ). 5. 16-26
Article History:
Received:October 27, 2012
Accepted:December 14, 2012
Collection year:2012
First Published:January 1, 2013

© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany


Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885